Laureano Simón, CEO of Oncomatryx, explains on “La Ventana” how this new treatment could reverse metastasis. A Spanish drug offers new hope to patients with metastatic cancer There is still no cure for cancer, but investment in research and technology is making it possible for many cancer patients to enjoy a better quality of life … Read more
BILBAO, Spain— Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU’s Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity … Read more
ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnologico e Innovacion (CDTI). … Read more
Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload.The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. … Read more
After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, … Read more
Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment – targeted ADCs. OMTX705, the Crown Jewel, has already proven high antitumor efficacy and unbeatable ADC safety in murine and non-human primate models. Phase I clinical trials in patients suffering metastatic solid tumors will … Read more
This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.
